Congenital antithrombin deficiency in patients with splanchnic vein thrombosis by Baiges Aznar, Anna et al.
This article has been accepted for publication and undergone full peer review but has not been 
through the copyediting, typesetting, pagination and proofreading process, which may lead to 
differences between this version and the Version of Record. Please cite this article as doi: 
10.1111/LIV.14342
 This article is protected by copyright. All rights reserved
MR. JOSE  FERRUSQUÍA-ACOSTA (Orcid ID : 0000-0001-8034-1291)
DR. VIRGINIA  HERNANDEZ-GEA (Orcid ID : 0000-0001-7937-984X)
DR. JUAN CARLOS  GARCÍA-PAGÁN (Orcid ID : 0000-0001-9032-4954)
Article type      : Original Articles
Editor               : Luca Valenti
Full title: Congenital antithrombin deficiency in patients with splanchnic vein thrombosis
Authors names and affiliations: 
Anna Baiges1*, María Eugenia de la Morena-Barrio2*, Fanny Turon1, Antonia Miñano2, José Alberto 
Ferrusquía1, Marta Magaz1, Juan Carlos Reverter3, Vicente Vicente2, Virginia Hernández-Gea1, Javier 
Corral2¥ and Juan Carlos García-Pagán1¥
1. Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic de Barcelona, Universitat 
de Barcelona, IDIBAPS and CIBERehd, Spain 
2. Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro 
Regional de Hemodonación, Universidad de Murcia, IMIB-Arrixaca, CIBERER, Murcia. Spain
3. Department of Haemotherapy and Haemostasis, Hospital Clínic de Barcelona, Spain
* AB and MEMB contributed equally to this work









This article is protected by copyright. All rights reserved
Corresponding author:
Juan Carlos García-Pagán. JCGARCIA@clinic.cat
Address: Villaroel 170, Barcelona 08036, Spain 
932275400 - 3314
Word count: Abstract word count: 243; Main text word count: 3733
Number of Figures: 3
Number of Tables: 3










This article is protected by copyright. All rights reserved
Abbreviations and acronyms in order of appearance
SVT Splanchnic vein thromboses
AT Antithrombin
CDG Congenital disorders of Glycosylation
PVT Portal Vein Thrombosis
BCS Budd Chiari Syndrome
FIIa Active Factor II
FXa Active Factor X
MAF Minor allele frequency
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Abstract
Background and aims. Splanchnic vein thromboses (SVT) are a rare condition that can be life-
threatening. The most severe thrombophilia associated to SVT is antithrombin (AT) deficiency, 
usually caused by SERPINC1 mutations. Although transitory AT deficiencies and congenital 
disorders of the N-glycosylation pathways (CDG) have been recently reported as causes of AT 
deficiency, the current AT clinical screening still only includes anti-FXa activity. This study aims to 
1) improve the detection of antithrombin deficiency in SVT and 2) characterize the features of 
antithrombin deficiency associated with SVT.
Methods. The study was performed in 2 cohorts: 1) 89 SVT patients with different underlying 
etiologies but in whom AT deficiency had been ruled out by classical diagnostic methods; and 2) 271 
unrelated patients with confirmed AT deficiency and venous thrombosis. Antithrombin was evaluated 
by functional (anti-FXa and anti-FIIa) and immunological methods (ELISA, crossed 
immunoelectrophoresis, western blot), and SERPINC1 sequencing was performed.
Results. In 4/89 patients (4.5%) additional alterations in AT were found (two had SERPINC1 
mutations, one had a specific variant causing transient AT deficiency and one patient had CDG). In 11 
of the 271 patients (4.1%) with AT deficiency and thrombosis, thrombosis was located at the 
splanchnic venous territory. 
Conclusions. AT deficiency may be underdiagnosed by current clinical screening techniques. 
Therefore, a comprehensive AT evaluation should be considered in cases of rethrombosis or doubtful 
interpretation of anti-FXa activity levels. SVT is a relatively common localization of the thrombotic 
event in patients with congenital AT deficiency.
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Lay Summary: 
Splanchnic vein thromboses are a rare condition. The most severe thrombophilia associated to 
splanchnic vein thromboses is antithrombin deficiency. Although new pathways for antithrombin 
deficiency have been recently reported, clinical screening still only includes antithrombin anti-factor 
Xa activity. We report and characterize antithrombin mutations most frequently associated with 
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Introduction
Thrombosis of the splanchnic veins (SVT) is a rare condition with a prevalence of less than 5 
cases every 10.000 inhabitants. However, despite being rare, SVT are a complex condition that can be 
life-threatening and lead to severe complications such as portal hypertension or intestinal ischemia[1].
The most frequent causes of SVT are major thrombophilic disorders and local factors, the 
latter being mainly abdominal inflammatory processes such as pancreatitis and surgical interventions. 
It is remarkable that in up to 30% of patients with a local factor there is also an underlying 
thrombophilic disorder, acting the local inflammation as trigger for the development of thrombosis[2].
Regardless availability of better diagnostic tools such as detection of Calreticulin or JAK2 
mutations[3,4], in around 30% of cases it is not possible to identify the thrombosis’ etiology and 
patients are finally classified as having an idiopathic thrombosis. Correctly classifying SVT thrombosis 
according to its etiology (major thrombophilic disorders vs local inflammation/idiopathic thrombosis) is 
highly relevant. Indeed, current guidelines only recommend long-term anticoagulation to prevent re-
thrombosis in those patients with underlying thrombophilic disorders. On the contrary, patients with 
idiopathic thrombosis or associated only to local factors will only receive anticoagulation in the setting 
of acute thrombosis[5,6]. Interestingly however, despite following these current guidelines, recent 
evidence shows a relevant incidence of new thrombotic events in patients with idiopathic thrombosis 
not treated with anticoagulants [7].
Antithrombin (AT) deficiency is one of the most severe hereditary thrombophilia [8–10]. 
Homozygote AT mutations are lethal disorders that cause intrauterine foetal death while heterozygote 
mutations lead to a hypercoagulable state with high probability of developing thrombosis [11]. 
AT deficiencies have been classified into two types: in type I, levels of AT are low;  in type II, 
AT levels are within the normal range but the AT molecule has impaired or null anticoagulant activity 
[12]. Several AT deficiency mechanisms have been described, being the most frequent genetic variants 
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The real incidence of SVT among carriers of AT deficiency has not been previously established 
[14]. However, from a clinical point of view, it is striking that despite the high prothrombotic risk of 
AT deficiency, the reported incidence of this alteration is very low among patients with splanchnic 
venous thrombosis, thus suggesting that AT deficiencies might be underestimated. There are increasing 
evidences on the low sensitivity of the current functional diagnostic tests to detect pathogenic 
mutations causing AT deficiency[13]. Moreover, it has been reported that the pathogenic effect of some 
SERPINC1 mutations might be exacerbated by environmental factors, leading to transient AT 
deficiency that would only be detected by functional methods. This would be the case of SERPINC1 
mutation p.Val30Glu[15]. Patients with this mutation would have normal levels and function of AT in 
baseline conditions but with a higher conformational susceptibility to stress, which would lead to 
deficiency of AT[15]. Similarly, post-traslational defects such as alterations and reduction of the N-
glycosylation pathways [16–18] caused by congenital disorders of glycosylation (CDG), which might be 
not detected by conventional functional methods, are also known to impaire AT function[17].
In addition, rendering the interpretation of AT levels even more difficult, acquired causes of 
low AT are much more common than hereditary AT deficiency  and, importantly, do not lead to 
hypercoagulable states. Therefore, when finding low levels of AT (< 80%) it is essential to exclude 
potential acquired etiologies before diagnosing hereditary AT deficiency. Several conditions can lead 
to low levels of AT and must be taken into account in the differential diagnosis (i.e. liver disease can 
decrease AT levels because of decreased hepatic synthesis; recent or active thrombosis lead to a 
general decrease of coagulation factors).
If AT deficiency is undetected and misdiagnosed, patients requiring anticoagulation could 
remain untreated with the consequent risk of re-thrombosis, not only SVT but also in other vascular 
territories. Diagnosing these patients would allow a correct risk stratification which could change the 
decision of prescribing chronic anticoagulation.
In this framework, we have designed the current study with 2 objectives: 1) to evaluate if it is 
possible to improve the detection of AT deficiency in patients with SVT using new diagnostic 
techniques 2) to report the features of AT deficiency that associate with SVT. 
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The study was performed in accordance with the International Guideline for Ethical Review of 
Epidemiological Studies and principles of the Declaration of Helsinki and approved by the ethics 
committee of Hospital Clínic de Barcelona and Hospital Universitario Reina Sofía de Murcia. Written 
informed consent from all patients was provided.
Patients and samples
This study is based in two different cohorts: 
- Cohort 1. Since 2003, all consecutive patients with SVT seen at Hospital Clínic de Barcelona (n = 
284) were asked for permission to obtain a blood sample for research purposes. Blood samples were 
stored at IDIBAPS Biobank facilities. As shown in supplementary figure 1, out of these 284 patients 
5 were diagnosed with AT deficiency (1.8%). Among the remaining 279 patients, we randomly 
selected 90 patients trying to represent the 3 main underlying etiologies (thrombophilia, local factor and 
idiopathic). Finally, one patient was discarded because inadequate storaged biobank sample. Thus, 
eighty-nine patients with SVT (68 with portal vein thrombosis (PVT) and 21 with Budd Chiari 
syndrome -BCS-) who had a complete etiological diagnostic work-up ruling out AT deficiency and 
from whom we had samples in the Biobank, were included in the study. AT deficiency had been 
clinically evaluated by a functional chromogenic method (anti- active factor X (FXa) activity test). 
Concomitant testing of other hepatic factors such as protein C and protein S had also been performed to 
assess acquired low AT levels. For each subject, clinical, haematological and laboratory data were 
collected. 
As detailed below, AT activity was assessed again at the biobank samples evaluating both anti-FXa 
and anti- active factor II (FIIa) activity. Also, total DNA was extracted from biobank peripheral blood 
samples by salting out procedures. In those patients showing AT levels below 80% (either by anti-
FXa and/or by anti-FIIa activity), a genetic study of SERPINC1 was performed (detailed below). 
Moreover, in all patients of this cohort analysis of plasma AT by western blot aiming to find aberrant 
forms of AT including hypoglycosylation and search of mutations responsible for transient AT 
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Three hundred forty-seven patients with previous thrombotic events (in any territory) and suspected AT 
deficiency based on the results of thrombophilic tests were referred during 22 years (1996-2018) to 
Hospital Universitario Reina Sofía de Murcia, the Spanish reference centre for this disorder. Plasma 
and DNA were collected and/or extracted as stated above and properly stored. Biochemical and 
functional characterization of plasma AT as well as genetic analysis were performed as detailed below. 
This study was performed in 271 patients with confirmed AT deficiency among the 347 referred 
patients. Familial studies were done in 206 cases.
Genetic analysis 
Genetic SERPINC1 variants were identified by sequencing the 7 exons and flanking regions, 
or the whole gene by Sanger’s or NGS methods as described before[17]. In cohort 1, genetic analysis 
was performed in every patient with AT anti-FXa or anti-FIIa activity below 80%: 21 SVT patients with two 
evidences of antithrombin deficiency independently of reduced levels of other hepatic proteins (all sequenced 
by Sanger’s method). Moreover, exons 2 and 7 were sequenced in all 89 patients with SVT by using Sanger 
sequencing.  In cohort 2, all 347 patients with congenital antithrombin deficiency (283 sequenced by Sanger’s 
method and 64 by NGS). Positive findings by NGS were always validated by Sanger sequencing. 
Gross rearrangements were assessed by multiplex ligation-dependent probe amplification 
(MLPA) using the SALSA MLPA Kit P227 SerpinC1 (MRC-Holland). Mutations were described 
following the Human Genome Variation Society Guidelines 
(http://varnomen.hgvs.org/recommendations/). The GenBank NM_000488.3 cDNA sequence was 
used as reference. Where available, HGMD (Human Gene Mutation Database) accession numbers are 
mentioned.
Biochemical and functional characterization of plasma antithrombin
AT anti-FXa and anti-FIIa activity were determined in citrated plasma by chromogenic 
methods. Values were expressed as percentages referred to a pool of 100 healthy subjects. AT 
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immunoelectrophoresis and/or ELISA (enzyme-linked immunosorbent assay). These methods were 
described in previous manuscripts[19].
Analysis of plasma AT forms included crossed immunoelectrophoresis and polyacrylamide gel 
electrophoresis under different conditions (denaturing and not denaturing) followed by immunological 
detection using conditions and reagents previously described[20]. 
Hypoglycosylation of AT and other hepatic proteins (1-antitrypsin and transferrin) in plasma was 
evaluated by western blot or HPLC (high-performance liquid chromatography) as described 
elsewhere [17].
The reported results were performed in samples collected long after the acute event in the cohort of 
patients with congenital AT deficiency (mean 42±76 months).
Alignment of antithrombin protein sequences among species
The alignment of antithrombin protein sequences with up to 49 species was performed by uniprot tool 
(https://www.uniprot.org/align/) and visualized by Jalview Version 2 [21].
Statistical analysis
Quantitative data are expressed as median and range. Qualitative data are expressed as percentages. 
Results
Cohort 1. Report of antithrombin deficiency in a large cohort of patients with SVT (PVT and BCS) in 
which this disorder had been originally ruled out.
Table 1 shows baseline characteristics of Cohort 1, including the etiology and the different 
thrombophilia present in this cohort. Overall, the 3 main etiologies were similarly represented: 28 
patients (31.5%) had a known thrombophilia, 26 (29.2%) were associated to a local factor with no 
underlying thrombophilia and in 35 patients (39.3%) neither thrombophilia nor local factor were 
identified and were considered idiopathic. 
AT deficiency had been, in the initial clinical screening, ruled out in all patients based on normal AT 
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synthesized factors) and the lack of familial history of neither thrombosis nor AT deficiency. The 
median values of AT activity measured as anti-FXa activity were 86.8 ± 17 %. Of note however, in this 
cohort there were 25 patients that presented levels of AT below 80% (median 68%, range: 48-79), 
which isolated could had been indeed considered AT deficiency. Nevertheless, these patients had a 
concomitant decrease in other coagulant factors such as protein C (median 72%, range: 33-99), protein 
S (median 82%, range: 68-130), FII (median 77%, range: 57-92) or FX (median 73%, range: 44- 143). 
Therefore, these decreased AT levels were considered acquired and clinically not relevant[22], 
assuming that they were due to either consumption or to a global decrease of liver factors synthesis.
Using the biobank samples of these 89 cases, AT function was reassessed by measuring both functional 
activity (by anti-FXa and anti-FIIa tests) and by immunological methods (Laurell and western blot). 
Similarly to what had been found in the clinical setting, this secondary screening showed that 21 cases 
had low AT levels in at least two tests (either AT anti-FXa, anti-FIIa activity or the two immunological 
assays). In these 21 cases with two positive findings suggesting AT deficiency (even if they also had 
decreased levels of protein C or protein S), SERPINC1 was sequenced and a genetic variation was 
found in 2 cases: 
- Patient 1 was a 48-year-old woman that presented a PVT without any associated local inflammatory 
process. During the PVT work-up she was diagnosed with JAK2 myeloproliferative neoplasm (MPN) 
and therefore anticoagulation was initiated. The remaining tests of the etiological study were 
considered normal. Despite the anticoagulation treatment this patient presented a more aggressive 
course with progression of PVT. Besides MPN, in the present analysis a mild AT deficiency was 
detected based on her anti-FXa activity of 70%. Moderately reduced levels of AT in plasma were 
verified by Laurell (84%) and Western blot, while in the genetic analysis a synonymous change 
affecting SERPINC1 in heterozygosis, c.468>T p.Ala156Ala, was identified. This genetic defect has 
been described as rs759369437 and has a minor allele frequency (MAF) of 0.00002 (data from Exome 
Aggregation Consortium Database, ExAC). Although there are synonymous mutations with pathogenic 
effect that may contribute to different disorders, we performed a familial study (Supplementary Figure 
2) that suggested that this SERPINC1 synonymous mutation might not have a pathogenic effect.   
- Patient 2 was a 60-year-old man with biliary pancreatitis that developed a splenic thrombosis. The 









This article is protected by copyright. All rights reserved
but as the Protein S levels were also slightly diminished (60%) the clinical interpretation had been that 
there was a global diminishment of coagulant factors secondary to reduced liver synthesis. Indeed, 
antigen levels revealed nearly normal AT levels in the biobank sample detected by Laurell (91%) and 
Western blot after SDS-PAGE (Figure 1). However, an abnormal AT form was detected in native gels 
but with no increased levels of the latent form (Figure 1). Crossed immunoelectrophoresis in the 
presence of heparin confirmed the type II deficiency without increase of AT forms with low heparin 
affinity (Figure 1). Sequencing of SERPINC1 revealed a heterozygous missense mutation in exon 3 
c.595G>A; p.Gly199Arg. The mutation affects a residue not conserved among the serpin superfamily 
located at the loop connecting the strand s1A and the helix E (Figure 1). This mutation, also reported 
as rs778341415, has a very low MAF= 0.00003 in ExAC, and is reported as a variant with uncertain 
significance at Clin Var (https://www.ncbi.nlm.nih.gov/clinvar/variation/432933/). This mutation is not 
included in the HGMD database (http://www.hgmd.cf.ac.uk/ac/all.php). Interestingly, the residue is 
highly conserved (80%) in ATs from 49 species (Figure 1). All these data support that this mutation 
caused a type II deficiency with impaired reactivity (type II RS). No long-term anticoagulation was 
administered and no re-thrombosis was observed after 9 years of follow-up. 
Afterwards, since mutations that are not usually detected by current functional assays [23] and 
that are responsible for transient AT deficiencies [15,24] are usually located in exons 2 and 7, these 
exons were sequenced in the whole cohort of 89 patients. One mutation was found:
- Patient 3 was a 51 year-old-woman with a known MPN that during follow-up developed a portal and 
splenic vein thrombosis. She presented strictly normal levels of AT anti-FXa (96%) and anti-FIIa 
(99%) and no AT deficiency according to immunological assays. Since the development of thrombosis 
she was on anticoagulation and has not presented new thrombotic events after 7 years of follow-up. The 
present study however has enabled to detect that she was a heterozygous carrier of the c.89T>A; 
p.Val30Glu mutation (AT Dublin)[15]. The presence of this mutation was confirmed in a new blood 
sample. 
Finally, in all 89 patients, analysis of plasma AT by western blot by using native and denaturing 
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- Patient 4 was a 63-year-old man with chronic pancreatitis due to CFTR gene mutation and chronic 
alcohol consumption. In this setting, he presented with an acute PVT. The thrombophilia study was 
negative (including AT anti-FXa levels of 94% and anti-FIIa 89%) and it was assumed that the PVT 
was secondary to local inflammation and pancreatitis. Anticoagulation was administered for 6 months. 
However, 2 years later the patient presented an acute pulmonary thromboembolism requiring resuming 
of anticoagulation. The current study displayed increased levels of N-hypoglycosylated forms of AT, 
which was verified by increased levels of N-hypoglycosylated forms of 1-antitrypsin and transferrin 
(Figure 2).
Summing up, overall four patients (4.5%) in whom AT deficiency had been previously 
clinically discarded, in the present study were found to have different AT mutations or deficiencies. 
Table 2 summarizes the more clinically relevant findings. 
Cohort 2. Report of congenital antithrombin mutations and defects associated to SVT in a large cohort 
of patients with AT deficiency. 
Two hundred seventy-one patients with confirmed congenital AT deficiency were included in 
this cohort. Among them, one hundred sixty-six cases had type II AT deficiency and 105 had type I 
AT deficiency. 
SVT was reported in 11 out of the 271 patients (4.1%). In all cases, SVT was the first 
thrombotic event and appeared in patients that were not previously on anticoagulation. Table 3 shows 
the characteristics and genetic defects of these patients. Four of the gene defects described in this 
study are being reported for the first time. Nine cases out of 11 (81.8%) had type I deficiency caused 
by a severe genetic defect. We point out two families (with 2 cases each) with type I deficiency and 
mesenteric thrombosis: one family presented a deletion affecting exon 4 and the other one a 31 bp 
deletion affecting the splicing signal and first 29 nucleotides of exon 7. Of note, only one among the 
166 patients with type II deficiency presented SVT. In this cohort, 1 patient had AT deficiency due to 
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The present study is the first to evaluate the incidence of undetected AT deficiencies among 
patients with SVT in whom a first initial screening had ruled out AT disorders. Moreover, the study of 
a large cohort of patients with AT deficiency has revealed new information on the role of this strong 
natural anticoagulant in SVT.
The analysis of cohort 1 shows that, currently, clinical assessment of AT function is mainly 
based on anti-FXa activity. Anti-FXa activity should adequately reflect the presence of both diminished 
levels of AT or impaired function, but the presence of the recently reported mutations causing transient 
deficiencies would be unnoticed by this method. More importantly however, we want to remark that 
sometimes it can be difficult to establish strict cut-off values of anti-FXa activity levels as there are 
many external agents that can affect its value, thus rendering them difficult to interpret: functional 
analysis of AT may identify cases with low anti-FXa activity levels that are not due to congenital 
deficiency. Impaired hepatic synthesis or coagulopathy caused by thrombin generation in the setting of 
acute thrombosis may lead to the detection of falsely low levels of AT, which are frequently 
accompanied by simultaneous low levels of other anticoagulant factors and that therefore are not 
considered to be clinically relevant in relation to risk of rethrombosis or need of treatment with long-
term anticoagulation.  
Based on the recent discovery of mutations causing transient AT deficiency and the finding of 
N-glycosylation related AT deficiencies, as well as the doubtful accuracy and reliability of AT anti-
FXa activity as a diagnostic test[13], we hypothesized that these new diagnostic techniques could play 
a role in facilitating the diagnosis of masked AT deficiencies in the setting of SVT. In cohort 1 we 
identified that 4.5% of patients previously considered to have a normal AT function presented an 
underlying AT disorder, which  is especially significant when contrasted with the general population 
prevalence of AT deficiency of 1/500-5000[25]. Importantly, in all these four patients the development 
of SVT had been exclusively attributed to either a concomitant local inflammation or to a MPN, but it 
was afterwards proved that they also had an AT disorder. These findings reinforce the concept that 
having two synergic prothrombotic conditions probably leads to an even higher hypercoagulable state, 
and that therefore a complete etiologic work-up should be performed in all patients, even if they 










This article is protected by copyright. All rights reserved
The analysis of Cohort 2, one of the largest worldwide cohort of patients with AT deficiency 
and a previous thrombotic event, demonstrates that thrombotic events in the portal and mesenteric 
veins is not an unusual localization among carriers of this severe thrombophilia. Indeed, in 4.1% of 
AT deficiency cases, the first thrombotic event was in the splanchnic territory. Although it is highly 
relevant if we take into account that the general population prevalence of SVT is less than 5 in 10.000 
inhabitants, it is not possible to infer from this cohort the incidence of SVT among patients with AT, 
as they were only diagnosed with AT deficiency after they had already developed SVT. The 
molecular analysis revealed that this localization is mainly restricted to cases with genetic defects 
causing severe AT deficiency, as most cases with SVT and AT deficiency had type I deficiency. 
Indeed, the percentage of patients with type I deficiency that developed SVT was significantly high: 
9/105 (8.6%). Our study identified four new SERPINC1 defects not previously described in patients 
with SVT, all causing type I deficiency, three by causing frameshift and generating a premature stop 
codon: c.495del (p.Ala166Profs*7), p.Arg164Aspfs*9 and c.1219-1_1248del (p.Val407_Ala414del); 
and the fourth by a structural variation (deletion of exon 4). Moreover, we point out two of these new 
SERPINC1 gene defects (deletion of exon 4 and c.1219-1_1248del (p.Val407_Ala414del) that 
affected two members of 2 different families developing SVT. On the other hand, only one case out of 
166 cases with type II deficiency developed SVT, suggesting that this patient could have presented an 
additional undetected risk factor favouring the development of this severe thrombotic event. 
Finally, disorders affecting the efficacy of the N-glycosylation can impair AT function and 
therefore increase the risk of thrombosis[17]. In this study we have identified two cases with SVT due 
to hypoglycosylation, one in each cohort. This finding strongly supports that this aberrant post-
translational modification causes a severe pro-thrombotic state.
We must acknowledge that one of our main limitations is the difficulty of differentiating the 
new mutations described in the present study from mere polymorphisms. However, taking into 
account the clinical setting of thrombosis and the low frequency in general population (MAF) of the 
mutations reported that reinforces their pathogenic role, it seems reasonable to assume causality 
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According to current evidence, it is recommended to screen patients with SVT for underlying 
thrombophilia and, given its high frequency among SVT, AT should be carefully studied. Figure 3 
suggests an AT screening algorithm depicting when to sequence SERPINC1 and to assess N-
glycosylation defects. Even though there is not enough evidence nor cost-effectiveness studies to 
suggest systematic screening of SERPINC1 mutations and CDG in all SVT patients (instead of 
performing only anti-FXa activity determinations), we consider that the findings of the present study, 
together with the small size of SERPINC1 and the development of massive sequencing methods that 
allow a relatively easy, fast and cheap sequencing of this gene, make it appropriate to recommend a 
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Figures legends
Figure 1. Characteristics of the p.Gly199Arg mutation identified in a patient with splanchnic vein 
thrombosis and antithrombin deficiency. A) Western blot of plasma antithrombin after native 
electrophoresis. Native antithrombin is pointed by a black arrow, while the variant antithrombin is 
pointed by a red arrow. B) Crossed immunoelectrophoresis in presence of heparin. The plasma 
antithrombin forms with low (L) and high (H) heparin affinity of a healthy control, the proband and a 
patient with antithrombin deficiency caused by a type II HBS mutation (AT Toyama; p.Arg79Cys) is 
shown. C) Localization of the Gly199 residue (red) in the structure of antithrombin. The reactive centre 
loop is marked in green. D) Alignment of antithrombin from 49 species at the region of interest, 
visualized by Jalview. Gly199 is pointed by an arrow in red.
Figure 2. Identification of N-hypoglycosylated forms of antithrombin (AT), 1-antitrypsin (1-
AT) and transferrin in plasma of a patient with splanchnic thrombosis. A healthy subject was used 
as negative control and a patient with PMM2-CDG (CDG) was used as a positive control. A) Western 
blot of plasma antithrombin after native electrophoresis. Native antithrombin is pointed by a black 
arrow, while the hypoglycosylated antithrombin is pointed by a red arrow. B) Western blot of plasma 
antithrombin and 1-antitrypsin after native electrophoresis. Native forms are pointed by a black arrow, 
while the hypoglycosylated forms are pointed by red arrows. C) HPLC identification of transferrin 
glycoforms. Asialo- and disialo transferrins are pointed by arrows. The percentage of informative 
glycoforms is also shown.
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Supplementary Figure 1. Flow chart of cohort 1.
Supplementary Figure 2. Plasma antithrombin in SVT Patient 1 and four relatives, all carriers of the 
p.Ala156Ala mutation in heterozygous state. Electrophoresis of plasma proteins was done under 
denaturing (SDS-PAGE) and native conditions and antithrombin was detected by western blot using a 
polyclonal antibody. As controls, we also studied plasma from a pool of 100 healthy blood donors, 
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(n = 68) 
BCS 
( n = 21) 
SVT (PVT + BCS) 
n = 89 
Baseline characteristics  n (%) or mean±SD  
Age at diagnosis (years) 44 ± 21 39 ± 12 43 ± 20 
Men (%) 44 (65) 6 (29) 50 (56%) 
Hemoglobin (g/dL) 128 ± 23 133 ± 27 129 ± 23 
Platelet count (x10
9
/L) 213 ± 127 285 ± 137 231 ± 132 
ALT (U/L) 47 ± 48 105 ± 133 61 ± 81 
AST (U/L) 40 ± 41 106 ± 184 56 ± 100 
FA (U/L) 292 ± 307 435 ± 240 326 ± 297 
GGT (U/L) 123 ± 167 182 ± 123 137 ± 159 
Bilirubin (mg/dL) 1 ± 2 3 ± 2 2 ± 2 
Albumin (g/L) 39 ± 8 33 ± 6 37 ± 8 
Prothrombin time (%) 79 ± 19 61 ± 16 75 ± 20 
Ascites 8 (12) 17 (81) 25 (28) 
Etiological factors  
Idiopathic 28 (41) 7 (33) 35 (39) 
Thrombophilia 15 (22) 13 (62) 28 (31) 
     Myeloproliferative neoplasm            8 (12) 8 (38) 16 (18) 
     Behcet      0 1 (5) 1 (1) 
     Paroxysmal hemoglobinuria       0 1 (5) 1 (1) 
     Antiphospholipid syndrome       1 (2) 2 (10) 3 (3) 
     Protein C deficiency      3 (4) 1 (5) 4 (4) 
     Prothrombin mutation G20210A 3 (44) 1 (5) 4 (4) 
Local factor 25(37) 1 (5) 26 (29) 
     Splenectomy  2 (3) 0 2 (0) 
     Omphalitis   1 (2) 0 1 (0) 
     Hepatic absces  1 (2) 0 1 (0) 









     Inflammatory bowel disease 0 1 (4.8) 1 (1) 
     Abdominal surgery    14 (20) 0 14 (15) 
PVT: Portal vein thrombosis; BCS: Budd Chiari Syndrome; SVT: splanchnic vein thrombosis 
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Table 2. Antithrombin deficiencies found in cohort 1, 89 patients with SVT in which antithrombin 
deficiency was ruled out in the first screening.  
 
AntiFXa AntiFIIa Prot C Prot S SVT Aetiology AT deficiency 
SERPINC1 variant 
Follow-up 
65% 70% 105% 61% Local factor 









c.89T>A (p.Val30Glu)  
Anticoagulation 
No re-thrombosis 




AntiFXa: anti-Factor X activated; antiFIIa anti-Factor II activated; Prot C: Protein C; Prot S: protein S, 
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Table 3. Genetic and clinical features of patients with antithrombin deficiency suffering from 
splanchnic vein thrombosis. 
 
Patient Anti-FXa SERPINC1 defect Deficiency 
1 54% c.236G>A; p.Arg79His (CM890016) Type II HBS 
2  50% c.1366G>C; p.Gly456Arg (CM940138) Type I 
3 52% c.481C>T; p.Arg161Ter (CM910056) Type I 
4  40% c.495del; p.Ala166Profs*7  
(New gene defect) 
Type I 
5  51% c.490del; p.Arg164Aspfs*9  
(New gene defect) 
Type I 
6  40% c.814dup; p.Tyr272Leufs*3 (CI072609) Type I 
7 37% c.1219-1_1248del; p.Val407_Ala414del 
(New gene defect) 
Type I 
Relative of P7 53% c.1219-1_1248del; p.Val407_Ala414del 
(New gene defect) 
Type I 
8  60% c.398A>C; p.Glu133Pro (CM940132) Type I 
9  50% Exon 4 deletion (New gene defect) Type I 
Relative of P9 52% Exon 4 deletion (New gene defect) Type I 
10 75% No SERPINC1 defect Type I 
11  63-91% No SERPINC1 defect Congenital disorder of 
glycosylation 
Anti-FXa: anti- factor X activated 
































AT deficiency assessment  
in the setting of SVT 
Levels of AT antiFXa > 80% Levels of AT antiFXa < 60% 
AT deficiency** 
Levels of AT antiFXa 60 - 80% 
Familial history of AT 
deficiency? 
SERPINC1 sequencing and  CDG screening 
Re-thrombosis ?  
 
No action needed 
 
No 
No action needed 
Yes 
Decreased levels of liver 
sinthesized factors?  
Yes No 
No Yes 
AT deficiency ** 
 
Familial history of AT deficiency? 
 
No Yes 
AT deficiency ** 
* In these cases it would be also interesting to sequence SERPINC1 and screen for CDG. However, as it is probably not cost-effective, more 
studies are warranted before recommending this attitude in clinical practice  
** Consider sequencing SERPINC1 and screen for CDG to further caractherize the type of AT deficiency 
 
Decreased levels of liver 
sinthesized factors?  
Yes No 
No action needed * No action needed * 
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